{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:55:48Z","timestamp":1740167748289,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41375-024-02195-w","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T13:04:02Z","timestamp":1709816642000},"page":"1435-1436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["There\u2019s life in the old dog yet: immunochemotherapy in Waldenstr\u00f6m\u2019s macroglobulinemia"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9782-9012","authenticated-orcid":false,"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"2195_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"2195_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41375-022-01732-9","volume":"37","author":"C Buske","year":"2023","unstructured":"Buske C, Jurczak W, Salem JE, Dimopoulos MA. Managing Waldenstrom\u2019s macroglobulinemia with BTK inhibitors. Leukemia. 2023;37:35\u201346.","journal-title":"Leukemia"},{"key":"2195_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1053\/j.seminhematol.2023.03.005","volume":"60","author":"C Buske","year":"2023","unstructured":"Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, et al. Report of consensus panel 1 from the 11(th) International Workshop on Waldenstrom\u2019s Macroglobulinemia on management of symptomatic, treatment-naive patients. Semin Hematol. 2023;60:73\u20139.","journal-title":"Semin Hematol"},{"key":"2195_CR4","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1097\/HS9.0000000000000520","volume":"5","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Ghia P. EHA endorsement of ESMO clinical practice guidelines for diagnosis, treatment, and follow-up of chronic lymphocytic leukemia. Hemasphere. 2021;5:e520.","journal-title":"Hemasphere"},{"key":"2195_CR5","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.22.01805","volume":"41","author":"C Buske","year":"2023","unstructured":"Buske C, Dimopoulos MA, Grunenberg A, Kastritis E, Tomowiak C, Mahe B, et al. Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenstrom\u2019s macroglobulinemia: a prospectively randomized trial of the European consortium for Waldenstrom\u2019s macroglobulinemia. J Clin Oncol. 2023;41:2607\u201316.","journal-title":"J Clin Oncol"},{"key":"2195_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/bjh.18643","volume":"201","author":"S Sarosiek","year":"2023","unstructured":"Sarosiek S, Gustine JN, Flynn CA, Leventoff C, Little M, White T, et al. Dose reductions in patients with Waldenstrom macroglobulinaemia treated with ibrutinib. Br J Haematol. 2023;201:897\u2013904.","journal-title":"Br J Haematol"},{"key":"2195_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.21.00838","volume":"40","author":"C Buske","year":"2022","unstructured":"Buske C, Tedeschi A, Trotman J, Garcia-Sanz R, MacDonald D, Leblond V, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstrom\u2019s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol. 2022;40:52\u201362.","journal-title":"J Clin Oncol"},{"key":"2195_CR8","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1200\/JCO.22.02830","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G, et al. Zanubrutinib versus ibrutinib in symptomatic Waldenstrom macroglobulinemia: final analysis from the randomized phase III ASPEN study. J Clin Oncol. 2023;41:5099\u2013106.","journal-title":"J Clin Oncol"},{"key":"2195_CR9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jmoldx.2023.03.010","volume":"25","author":"AN Markou","year":"2023","unstructured":"Markou AN, Bagratuni T, Tsakiri C, Tserpeli V, Skourti S, Mavrianou Koutsoukou N, et al. Highly sensitive detection method of CXCR4 tumor hotspot mutations by drop-off droplet digital PCR in patients with IgM monoclonal gammopathies. J Mol Diagn. 2023;25:502\u201312.","journal-title":"J Mol Diagn"},{"key":"2195_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41375-022-01762-3","volume":"37","author":"I Dogliotti","year":"2023","unstructured":"Dogliotti I, Jimenez C, Varettoni M, Talaulikar D, Bagratuni T, Ferrante M, et al. Diagnostics in Waldenstrom\u2019s macroglobulinemia: a consensus statement of the European consortium for Waldenstrom\u2019s macroglobulinemia. Leukemia. 2023;37:388\u201395.","journal-title":"Leukemia"},{"key":"2195_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.seminhematol.2023.03.007","volume":"60","author":"R Garcia-Sanz","year":"2023","unstructured":"Garcia-Sanz R, Varettoni M, Jimenez C, Ferrero S, Poulain S, San-Miguel JF, et al. Report of consensus panel 3 from the 11th International Workshop on Waldenstrom\u2019s macroglobulinemia: recommendations for molecular diagnosis in Waldenstrom\u2019s macroglobulinemia. Semin Hematol. 2023;60:90\u20136.","journal-title":"Semin Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02195-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02195-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02195-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:02:20Z","timestamp":1717416140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02195-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2195"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02195-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"29 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Christian Buske: honoraria: Roche\/Genentech, Janssen, BeiGene, Novartis, Pfizer, AbbVie, Gilead Sciences, Celltrion, MorphoSys, Regeneron, Hexal, Bayer, SOBI; consulting or advisory role: Gilead Sciences, Janssen, Roche, Pfizer, BeiGene, Celltrion, AbbVie, Regeneron, MorphoSys, Novartis, Bayer, SOBI; speakers' bureau: Roche, Janssen, BeiGene, Celltrion, AbbVie, Pfizer, Gilead Sciences, Bayer, Hexal, MorphoSys, Regeneron, Novartis; research funding: Roche\/Genentech, Janssen, Celltrion, MSD, Amgen, Bayer (Inst), AbbVie, Pfizer. Efstathios Kastritis: honoraria: Janssen, GSK, Pfizer, Sanofi; research support: Janssen, GSK, Pfizer; travel support: Janssen, Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}